Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research.
Keywords: CAR-T cell therapy; dendritic cell vaccines; genetically engineered mouse models; glioma; humanized mice; immune checkpoint inhibitors; immunotherapy; oncolytic virotherapy; organoids; syngeneic murine glioma lines.